FOSTER CITY, Calif. – May 8, 2024 - Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for first quarter 2024 and provided a business update. "In the first quarter, we made great progress across a number of our strategic objectives that support both the near- and long-term growth of Mirum while maintaining a strong financial position," said Chris Peetz, chief executive officer at Mirum. "Our commercial business is performing well, and we saw continued growth in demand for LIVMARLI g ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38981 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) | Delaware | 83-1281555 | | --- | --- | | (S ...

Financial Data and Key Metrics Changes - Total revenue for Q4 2023 was $69.6 million, with total revenue for the year ending December 31, 2023, at $186.4 million, compared to $27.9 million and $77.1 million for Q4 and the full year 2022 respectively, indicating significant growth [60] - Net product sales for the year were $178.9 million, reflecting a year-over-year growth of 142% [45][60] - The net loss for the year was $160.9 million or $3.94 per share, which included non-cash stock-based compensation of $35 million and intangible amortization of $10.4 million [61] Business Line Data and Key Metrics Changes - LIVMARLI's total global net product sales grew to $41.4 million in Q4, with U.S. sales at $31.4 million and $111 million for the year, representing approximately 63% year-over-year growth [54][60] - CHENODAL and CHOLBAM generated net product sales of $28.1 million in Q4, marking the highest quarter-to-date for bile acid products [70] Market Data and Key Metrics Changes - The company expects net product sales to reach $310 million to $320 million in 2024, representing over 70% growth from 2023 [55][60] - The international market for LIVMARLI is showing strong uptake, although variability in quarterly revenue is anticipated [54] Company Strategy and Development Direction - The company aims to leverage its expertise in cholestasis and expand its commercial portfolio, focusing on upcoming label expansion opportunities and pipeline growth [46][50] - The strategy includes preparing for multiple regulatory and clinical catalysts, with a PDUFA date for LIVMARLI and PFIC set for March 13, 2024 [48][57] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of LIVMARLI and the overall business, highlighting the strong demand and progress in international markets [19][54] - The company is well-funded with cash and investments totaling $286.3 million as of December 31, 2023, indicating a strong financial position to support future growth [62] Other Important Information - The company welcomed Dr. Joanne Quan as the new Chief Medical Officer, emphasizing her leadership and expertise in driving future value creation [51] - The company is focused on addressing unmet medical needs in rare diseases, particularly through the development of therapies for conditions like PSC and PBC [59][117] Q&A Session Summary Question: Can you discuss the 2024 net product sales guidance and contributions from LIVMARLI versus CHENODAL and CHOLBAM? - Management refrained from providing specific product-level guidance but noted strong dynamics across products, with expectations of mid-single-digit growth for bile acid products and continued strong growth for LIVMARLI [66] Question: What are the expectations for the VANTAGE study and its impact on outcomes? - Management indicated that significant impact on pruritus would be clinically meaningful and that the study is designed to address an important unmet medical need [88][90] Question: Can you provide details on the sales numbers for LIVMARLI and bile acid products for Q4? - LIVMARLI totaled $41.4 million worldwide, with $31.4 million from the U.S. and $10 million internationally, while bile acid products generated $28.1 million for Q4 [105]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to _______________ Commission File Number 001-38981 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Indicat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to _______________ Commission File Number 001-38981 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) | Delaware | ...

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Andrew McKibben – Vice President-Investor Relations and Finance Chris Peetz – President and Chief Executive Officer Peter Radovich – Chief Operating Officer Pam Vig – Head-Research and Development Conference Call Participants Steve Seedhouse – Raymond James Mani Foroohar – SVB Leerink Thomas Yip – H.C. Wainwright Operator Good afternoon, and thank you all for joining. I would like to wel ...

Genetic disease leading to bile acid build-up and progressive liver damage 1 in every 50,000 to 100,000 births in the US and Europe This presentation contains "forward-looking" statements that are based on our management's beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our pending acquisition of CHOLBAM and CHENODAL and the ...

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q1 2023 Earnings Conference Call May 6, 2023 4:30 PM ET Company Participants Andrew McKibben - Vice President, Investor Relations and Finance Chris Peetz - President & Chief Executive Officer Peter Radovich - Chief Operating Officer Pamela Vig - Head of R&D Conference Call Participants Mani Foroohar - SVB Securities Ryan Deschner - Raymond James Operator Operator Ladies and gentlemen, welcome to the Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to _______________ Commission File Number 001-38981 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) | Delaware | 83-1281555 | | --- | --- | | ( State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identification No.) ...

Mirum Pharmaceuticals, Inc. (MIRM) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Corporate Participants Andrew McKibben - Vice President, Investor Relations and Finance Chris Peetz - President and Chief Executive Officer Ian Clements - Chief Financial Officer Peter Radovich - Chief Operating Officer Pamela Vig - Head of R&D Conference Call Participants Jessica Fye - JPMorgan Mani Foroohar - SVB Securities Josh Schimmer - Evercore Ryan Deschner - Raymond James David Lebowitz - Citi Brian Skorney ...